Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06385821
Other study ID # GriQv-ch-III-22
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 21, 2022
Est. completion date October 9, 2023

Study information

Verified date November 2023
Source NPO Petrovax
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the compared vaccines in terms of the "proportion of vaccinated with seroconversion in paired sera of the hemagglutination inhibition reaction obtained before and after vaccination".


Description:

The main questions it aims to answer are: 1. To compare the immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the compared vaccines in terms of "geometric mean antibody titers after vaccination" 2. Evaluate the immunogenicity of the Grippol Quadrivalent vaccine and the Grippol plus vaccine according to the following indicators: - Proportion of those vaccinated with seroconversion and geometric mean titer of antibodies to the fourth additional strain of compared vaccines - Multiplicity of the increase in the geometric mean titer of antibodies to 4 strains of the influenza virus in paired sera of the hemagglutination inhibition reaction after vaccination in relation to the initial values of antibody titers - Seroprotection (proportion (%) vaccinated with antibody titer ≥ 1:40 to 4 strains of influenza virus in paired sera of the hemagglutination inhibition reaction after vaccination) 3. Evaluate the effectiveness of the Grippol Quadrivalent vaccine and the Grippol plus vaccine according to the following indicators: - Incidence of Influenza and ARI (Month 1-Month 6 after vaccination) - Severity and duration of reported cases of influenza and ARI, presence of complications 4. Assess the reactogenicity of the Grippol Quadrivalent vaccine and the Grippol plus vaccine in children aged 6 months to 5 years (inclusive): - Frequency and nature of general and local post-vaccination reactions (7-day follow-up period after vaccine administration) 5. Assess the safety of Grippol Quadrivalent and Grippol Plus in children aged 6 months to 5 years (inclusive)


Recruitment information / eligibility

Status Completed
Enrollment 824
Est. completion date October 9, 2023
Est. primary completion date June 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 5 Years
Eligibility Inclusion Criteria: 1. Male and female children aged 6 months to 5 years inclusive at the time of vaccination. 2. Availability of Informed consent to participate in the study, signed by one of the parents. 3. The diagnosis is "healthy", established according to standard clinical, laboratory and instrumental methods of examination carried out at screening, according to the assessment of the researcher, as well as anamnesis data (absence of acute and chronic diseases of the respiratory, cardiovascular, nervous systems, dysfunction liver or kidneys). 4. Negative result of a rapid test for SARS-CoV-2 antigen at screening. 5. For children aged 6 to 11 months inclusive: children born at gestational age =37 weeks weighing =2.5 kg. 6. Parental consent to cooperate in good faith with the investigator and center staff, attend scheduled visits, complete the self-monitoring diary, and follow the protocol. Exclusion Criteria: 1. Vaccination with any influenza vaccine within the previous 6 months. Vaccination with other vaccines, according to the national vaccination schedule, is allowed no later than 30 days before the introduction of the study vaccine, and no earlier than 30 days after the administration of the study vaccines. 2. Participation in a clinical trial of a vaccine, medicinal product, or medical device less than 30 days prior to screening. 3. Hypersensitivity to any of the components of the studied vaccines or severe post-vaccination complications to any vaccine in history. 4. The presence at the time of screening of acute infectious diseases of any localization, or the presence of a history of acute infectious and non-infectious diseases less than 14 days before screening. 5. Body temperature in the armpit =37.0°C at screening or before the introduction of the vaccine. 6. History of significant chronic diseases, such as malignant neoplasms or blood diseases, autoimmune diseases, insulin-dependent diabetes mellitus, chronic diseases of the lungs, liver or kidneys, cardiovascular, nervous systems, secondary, primary and induced immunodeficiency, HIV- infections, as well as other significant, according to the researcher, diseases. 7. A history of seizures or a progressive neurological disease. 8. History of Guillain-Barré syndrome (post-infectious demyelinating polyradiculoneuropathy of autoimmune etiology). 9. Use of antipyretics, including non-steroidal anti-inflammatory drugs less than 24 hours before screening and vaccination; antibacterial drugs of systemic action - less than 72 hours before screening and vaccination; anticoagulants - less than 3 weeks before screening and vaccination; immunoglobulins, blood products - less than 3 months before screening and vaccination; long-term use of systemic corticosteroids (prednisolone or equivalent for more than 2 consecutive weeks) - less than 3 months before vaccination screening. 10. Surgery performed less than 3 months prior to screening. 11. Children of research team members or research facility staff involved in this clinical trial. 12. Orphans, children left without parental care. 13. Any other medical or social condition that, in the opinion of the investigator, precludes the participation of the child in this study.

Study Design


Intervention

Biological:
Grippol Quadrivalent
Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
Grippol Plus
Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).

Locations

Country Name City State
Russian Federation State Autonomous Healthcare Institution of the Sverdlovsk Region "Children's City Clinical Hospital No. 11" Ekaterinburg
Russian Federation Federal State Budgetary Research Institution "Russian research center of surgery named after academician B.V. Petrovsky" Moscow
Russian Federation State Budgetary Healthcare Institution "Children's City Clinical Hospital No.9 named after G.N. Speransky of Moscow Healthcare Department" Moscow
Russian Federation State Budgetary Health Institution of the Perm Territory "City Children's Clinical Polyclinic No. 5 Perm
Russian Federation Limited Liability Company "Clinic USI 4D" Pyatigorsk
Russian Federation Federal State-Financed Institution Pediatric Research and Clinical Center for Infectious Diseases under the Federal Medical Biological Agency Saint Petersburg
Russian Federation Limited Liability Company " Energiia Zdoroviya" Saint Petersburg
Russian Federation Limited Liability Company Medical technology Saint Petersburg
Russian Federation Limited Liability Company PiterClinica Saint Petersburg
Russian Federation St. Petersburg State Budgetary Health Institution "Children's City Polyclinic No. 45 of the Nevsky District" Saint Petersburg
Russian Federation St. Petersburg State Budgetary Healthcare Institution City Polyclinic No.106 Children's Polyclinic Department No. 37 Saint Petersburg
Russian Federation State Budgetary Healthcare Institution of the Samara region "Samara Regional Children's Clinical Hospital named after N.N. Ivanova" Samara
Russian Federation Limited Liability Company Center DNK-issledovaniy Saratov
Russian Federation Federal State Budgetary Educational Institution of Higher Education "Tyumen State Medical University" of the Ministry of Healthcare of the Russian Federation Tyumen

Sponsors (1)

Lead Sponsor Collaborator
NPO Petrovax

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary To prove non-inferior immunogenicity of the Grippol Quadrivalent vaccine when compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three matching strains of the compared vaccines Proportion of vaccinated seroconverters in paired hemagglutination inhibition test sera obtained before and after vaccination
Seroconversion is defined as:
increase in antibody titer to influenza virus strains to = 1:40 (with initial antibody titer < 1:10); or
an increase in antibody titer by 4 or more times compared to the initial titer (with an initial antibody titer = 1:10) in paired sera RTGA after vaccination.
The initial antibody titer will be the titers of antibodies to influenza virus antigens in the hemagglutination inhibition reaction obtained during screening. Post-vaccination titres will be those obtained on Day 25±3 after a single dose of vaccine in children 36 months to 5 years of age or a second dose of vaccine in children 6 to 35 months of age.
Baseline to Day 25±3
Secondary Geometric mean antibody titers Geometric mean antibody titers after vaccination for three matching strains Baseline to Day 25±3
Secondary Proportion of those vaccinated with seroconversion and geometric mean titer Proportion of those vaccinated with seroconversion and geometric mean titer of antibodies to the fourth additional strain of compared vaccines Baseline to Day 25±3
Secondary Multiplicity of the increase in the geometric mean titer Multiplicity of the increase in the geometric mean titer of antibodies to 4 strains of the influenza virus in paired sera of the hemagglutination inhibition reaction after vaccination in relation to the initial values of antibody titers Baseline to Day 25±3
Secondary Seroprotection Seroprotection (proportion (%) vaccinated with antibody titer = 1:40 to 4 strains of influenza virus in paired sera of the hemagglutination inhibition reaction after vaccination) Baseline to Day 25±3
Secondary Incidence of influenza and acute respiratory infections (ARI) • Incidence of influenza and ARI (Month 1 - Month 6 after vaccination) Month 1-6
Secondary The severity and duration of registered cases of influenza and acute respiratory infections (ARI), the presence of complications The severity and duration of registered cases of influenza and ARI, the presence of complications (Month 1 - Month 6 after vaccination) Month 1 to Month 6
Secondary To assess the reactogenicity of the vaccine Grippol Quadrivalent and the vaccine Grippol plus Frequency and nature of general and local post-vaccination reactions (7-day follow-up period after vaccine administration) First 7 days after vaccination
Secondary Frequency and nature of SAEs Frequency and nature of SAEs (Day 1-Month 6) Baseline to month 6
Secondary Frequency and nature of medically attended AEs Frequency and nature of medically attended AEs (Month 1-Month 6) Baseline to month 6
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A